Q2 2024 · 13F-HR
Rock Springs Capital Management LPholdings as filed
Filed 2024-08-14 · accession 0001172661-24-003467
$3.32B
Reported value
112
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $265.2M | 7.98% | 2,460,417 | Common | SOLE |
| 91324P102 | UNH | UNITEDHEALTH GROUP INC | $140.0M | 4.22% | 275,000 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $132.8M | 4.00% | 298,500 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $129.4M | 3.90% | 940,000 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $110.0M | 3.31% | 121,500 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $98.6M | 2.97% | 229,250 | Common | SOLE |
| 00404A109 | ACHC | ACADIA HEALTHCARE COMPANY IN | $79.5M | 2.39% | 1,177,500 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $79.1M | 2.38% | 1,924,072 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC | $78.0M | 2.35% | 4,077,500 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $68.8M | 2.07% | 245,499 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $63.0M | 1.89% | 817,500 | Common | SOLE |
| 358039105 | FRPT | FRESHPET INC | $62.1M | 1.87% | 480,000 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $60.8M | 1.83% | 250,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $60.6M | 1.82% | 1,772,038 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $59.2M | 1.78% | 1,001,073 | Common | SOLE |
| 45168D104 | IDXX | IDEXX LABS INC | $58.2M | 1.75% | 119,500 | Common | SOLE |
| 00857U107 | — | AGILON HEALTH INC | $58.2M | 1.75% | 8,900,000 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $56.7M | 1.71% | 500,000 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $55.1M | 1.66% | 147,408 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $54.2M | 1.63% | 808,356 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $52.6M | 1.58% | 1,280,493 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $51.8M | 1.56% | 1,398,994 | Common | SOLE |
| 71944F106 | PHR | PHREESIA INC | $51.3M | 1.54% | 2,417,500 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $50.8M | 1.53% | 550,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $49.6M | 1.49% | 1,272,877 | Common | SOLE |
| 955306105 | WST | WEST PHARMACEUTICAL SVSC INC | $47.9M | 1.44% | 145,500 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $47.7M | 1.44% | 265,000 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $45.7M | 1.38% | 1,081,500 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $45.0M | 1.36% | 1,044,261 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $44.9M | 1.35% | 284,000 | Common | SOLE |
| 450056106 | IRTC | IRHYTHM TECHNOLOGIES INC | $42.8M | 1.29% | 397,500 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $39.6M | 1.19% | 290,000 | Common | SOLE |
| 45784P101 | PODD | INSULET CORP | $39.4M | 1.18% | 195,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $39.3M | 1.18% | 999,862 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $36.8M | 1.11% | 4,482,265 | Common | SOLE |
| 114340102 | AZTA | AZENTA INC | $36.6M | 1.10% | 696,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $36.6M | 1.10% | 943,195 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $34.7M | 1.05% | 1,163,973 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $33.4M | 1.01% | 9,283,492 | Common | SOLE |
| 93403J106 | WRBY | WARBY PARKER INC | $33.4M | 1.01% | 2,080,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $31.3M | 0.94% | 1,185,654 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $30.8M | 0.93% | 127,500 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $25.2M | 0.76% | 1,074,261 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $24.8M | 0.75% | 170,000 | Common | SOLE |
| 53228F101 | LFST | LIFESTANCE HEALTH GROUP INC | $23.7M | 0.71% | 4,827,700 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $22.5M | 0.68% | 1,297,873 | Common | SOLE |
| 695127100 | PCRX | PACIRA BIOSCIENCES INC | $22.5M | 0.68% | 785,000 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $22.4M | 0.67% | 505,786 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $22.4M | 0.67% | 3,619,258 | Common | SOLE |
| 670100205 | NVO | NOVO-NORDISK A S | $21.1M | 0.63% | 147,500 | Common | SOLE |
| 687793109 | OSCR | OSCAR HEALTH INC | $19.8M | 0.60% | 1,251,500 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $19.4M | 0.58% | 255,989 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $19.4M | 0.58% | 105,569 | Common | SOLE |
| 457730109 | INSP | INSPIRE MED SYS INC | $17.4M | 0.52% | 130,000 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $16.5M | 0.50% | 3,698,374 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $16.3M | 0.49% | 461,028 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $14.5M | 0.44% | 1,292,637 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $14.2M | 0.43% | 756,931 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $14.2M | 0.43% | 419,030 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $13.8M | 0.42% | 381,192 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $13.0M | 0.39% | 289,400 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $12.9M | 0.39% | 625,048 | Common | SOLE |
| 680710100 | — | OLINK HLDG AB | $12.7M | 0.38% | 500,000 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $12.4M | 0.37% | 60,250 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $12.4M | 0.37% | 151,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $12.1M | 0.36% | 1,218,580 | Common | SOLE |
| 64157F103 | NVROEUR | NEVRO CORP | $11.6M | 0.35% | 1,381,500 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $11.5M | 0.35% | 658,338 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $10.0M | 0.30% | 428,571 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $9.2M | 0.28% | 404,335 | Common | SOLE |
| 670002401 | NVAX | NOVAVAX INC | $8.5M | 0.26% | 675,000 | Common | SOLE |
| 00437E102 | ACCDUSD | ACCOLADE INC | $8.2M | 0.25% | 2,290,000 | Common | SOLE |
| 268311107 | EDAP | EDAP TMS S A | $8.0M | 0.24% | 1,475,000 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $7.5M | 0.23% | 199,855 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $7.5M | 0.22% | 760,007 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $7.3M | 0.22% | 1,555,004 | Common | SOLE |
| 05156V102 | AUPH | AURINIA PHARMACEUTICALS INC | $6.7M | 0.20% | 1,179,740 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $6.1M | 0.18% | 57,000 | CALL | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $6.1M | 0.18% | 3,046,782 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $5.9M | 0.18% | 249,923 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $5.6M | 0.17% | 2,300,059 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $5.5M | 0.17% | 5,513,788 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $5.4M | 0.16% | 140,700 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $4.7M | 0.14% | 9,573,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $4.5M | 0.14% | 727,673 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $4.5M | 0.13% | 1,053,647 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $4.4M | 0.13% | 378,932 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $4.4M | 0.13% | 127,558 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $4.1M | 0.12% | 384,996 | Common | SOLE |
| 745848101 | LUNG | PULMONX CORP | $4.1M | 0.12% | 652,400 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $4.0M | 0.12% | 401,196 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $3.6M | 0.11% | 1,032,988 | Common | SOLE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $3.6M | 0.11% | 677,005 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $3.0M | 0.09% | 2,753,495 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $2.9M | 0.09% | 3,266,960 | Common | SOLE |
| 761299AB2 | TVTX 2.5 09/15/25 | TRAVERE THERAPEUTICS INC | $2.9M | 0.09% | 3,250,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $2.8M | 0.09% | 3,003,259 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $2.7M | 0.08% | 787,808 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $2.6M | 0.08% | 65,600 | CALL | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $2.5M | 0.07% | 1,266,546 | Common | SOLE |
| 00653A107 | ADAPY | ADAPTIMMUNE THERAPEUTICS PLC | $2.4M | 0.07% | 2,425,468 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $1.9M | 0.06% | 471,958 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $1.7M | 0.05% | 989,990 | Common | SOLE |
| 85209E109 | — | SPRUCE BIOSCIENCES INC | $1.4M | 0.04% | 2,609,125 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $1.3M | 0.04% | 178,963 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $1.2M | 0.04% | 35,719 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $1.2M | 0.04% | 1,200,409 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $815,162 | 0.02% | 181,147 | Common | SOLE |
| 92731L106 | — | VINCERX PHARMA INC | $722,292 | 0.02% | 891,719 | Common | SOLE |
| 64157FAC7 | — | NEVRO CORP | $483,261 | 0.01% | 500,000 | Common | SOLE |
| 00444T209 | TLPH | TALPHERA INC | $281,649 | 0.01% | 316,460 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $21,444 | 0.00% | 134,028 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.